

GF/B46/EDP01 *Decision on the Secretariat's Recommendation on Funding from the 2020-2022 Allocation*

Approved on 24 November 2021

The Board:

1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER01 ("Table 1");
2. Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

Table 1: Secretariat’s Recommendation on Funding from the 2020-2022 Allocation

Please note that each country name is linked to the extranet site where supporting documents are available for review.

N	Applicant	Disease Component	Grant Name ¹	Grant End Date	Currency	Total Program Budget ²	Catalytic Funds in Grant	Domestic Commitment ³	Unfunded Quality Demand
1	Belize	HIV	BLZ-H-SSB	31/12/2024	US\$	2,998,946	-	HIV: 10,650,505	987,491
2	Bolivia (Plurinational State)	Malaria	BOL-M-UNDP	31/12/2024	US\$	5,555,895	-	Malaria: 15,133,282	694,665
3	Botswana	HIV/TB	BWA-C-BMoH	31/12/2024	US\$	23,314,605	2,800,000	HIV: 198,834,595 TB: 6,738,067	5,688,189
4	Burundi	RSSH	BDI-S-UGADS	31/12/2023	US\$	8,532,984	-	RSSH commitments included in disease commitment numbers, HIV: 7,252,033 TB: 1,670,784 Malaria: 12,930,529	34,225,120
5	Comoros	HIV/TB	COM-C-MOH	31/12/2024	EUR	1,501,349	-	HIV: 441,271 TB: 303,954 RSSH: 1,823,538	1,436,089
6		Malaria	COM-M-PNLP	31/12/2024	EUR	4,833,906	-	Malaria: 1,078,313 RSSH: 1,823,538	1,094,216
7	Dominican Republic	HIV	DOM-H-CONAVIH	31/12/2024	US\$	9,210,394	-	HIV: 72,924,430	2,412,437
8			DOM-H-IDCP	31/12/2024	US\$	6,785,445	-		
9	El Salvador	HIV	SLV-H-PLAN	31/12/2024	US\$	7,669,857	-	HIV: 135,090,618 TB: 29'497'958	2,441,809
10		HIV/TB	SLV-C-MOH	31/12/2024	US\$	11,587,015	-	TB: 29'497'958	3,714,634
11	Jamaica	HIV	JAM-H-MOH	31/12/2024	US\$	13,388,613	1,900,000	HIV: 38,536,976	2,954,347

¹ The Grant names are subject to change based on the ISO code.

² The Program budget for the Grant may be higher than the Program budget being recommended to the Board for approval where COVID-19 Response Mechanism funding has been integrated into the Grant.

³ Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies. Please note that the domestic commitments included in this report are recorded as of the date of the GAC meeting and may be updated during implementation for countries that have been granted policy flexibilities.

12	Multicountry HIV MENA IHAA	HIV	QMZ-H-FA	31/12/2024	US\$	7,500,000	7,500,000	Multicountry grants exempt from co-financing requirements. ⁴	-
13	Middle East Response (MER)	HIV, TB, Malaria	QSF-Z-IOM	31/12/2024	US\$	50,587,299	-	As a non-CCM applicant, MER is not required to meet co-financing requirements	35,619,345
14	Nicaragua	HIV/TB	NIC-C-WVI	31/12/2024	US\$	12,266,255	-	HIV: 54,068,478 TB: 19,019,212	675,856
15		Malaria	NIC-M-REDNICA	31/12/2024	US\$	6,426,652	-	Malaria: 21,760,729	616,253
16	Niger	TB	NER-T-MSP	31/12/2024	EUR	13,341,202	1,813,300	TB: 5,282,992	3,907,875
17	Sri Lanka	TB	LKA-T-MOH	31/12/2024	US\$	3,039,336	-	TB: 13,779,989	1,240,230
18	Suriname	HIV	SUR-H-MOH	31/12/2024	US\$	2,355,648	-	HIV: 7,138,278	242,000

⁴ Multicountry grants (comprised solely of catalytic funding) are exempt from co-financing requirements.